We See The World From All Sides and Want YOU To Be Fully InformedIn fact, intentional disinformation is a disgraceful scourge in media today. So to assuage any possible errant incorrect information posted herein, we strongly encourage you to seek corroboration from other non-VT sources before forming educated opinion. In addition, to get a clear comprehension of VT's independent non-censored media, please read our Policies and Disclosures.
Due to the nature of uncensored content posted by VT's fully independent international writers, VT cannot guarantee absolute validity. All content is owned by the author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners, or technicians. Some content may be satirical in nature. All images are the full responsibility of the article author and NOT VT. About VT - Comment Policy
the video is very offensive on the mean of seeing how much death in Usa occurred……
Biden is too old to be a president, his brain is very insANE FOR WHAT TOLD TO pUTIN WHICH IS A VERY STATIST WHEN bIDEN IS A PUPPET OF DEEP STATE, AND ZIONIST REGIME INSTATED IN uSA FROM MANY YEARS
From CMS – Medicare
COVID-19 Update: FDA Revoked the EUA for Bamlanivimab When Administered Alone
On April 16, the FDA revoked the Emergency Use Authorization (EUA) for bamlanivimab, when administered alone, due to a sustained increase in COVID-19 viral variants in the U.S. that are resistant to this antibody therapy. The FDA determined that the known and potential benefits of bamlanivimab, when administered alone, no longer outweigh the known and potential risks.
Medicare will cover and pay for bamlanivimab, when administered alone, for dates of service from November 10, 2020 – April 16, 2021.
The FDA indicates that alternative monoclonal antibody therapies remain appropriate to treat COVID-19 patients, and health care providers may continue using these authorized therapies when administered together:
Casirivimab & imdevimab
Bamlanivimab & etesevimab
Fact Sheet for Health Care Providers EUA of Casirivimab and Imdevimab Section 15, Antiviral Resistance
Fact Sheet for Health Care Providers EUA of Bamlanivimab and Etesevimab Section 15, Antiviral Resistance
Monoclonal Antibody COVID-19 Infusion webpage
The Medicare Learning Network®, MLN Connects®, and MLN Matters® are registered
trademarks of the U.S. Department of Health and Human Services (HHS). Paid for by HHS.
what is not identified.. is where these new Gamma Globulin Infusions are failing
Comments are closed.